Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment of ...
The choice of loop diuretic for decongestion in patients hospitalized with heart failure (HF) may make little difference to survival or readmission risk over the next year, at least when deciding ...
CHICAGO -- The choice between furosemide and torsemide didn't matter for longer-term clinical outcomes of hospitalized heart failure patients, according to the comparative effectiveness trial ...
The FDA approved the first furosemide (Furoscix) formulation for subcutaneous self-administration by patients with congestive heart failure, scPharmaceuticals announced. The IV-equivalent formulation ...
CHICAGO, IL—The choice of loop diuretic doesn’t make a difference in how patients hospitalized for heart failure fare, at least when it comes to their risk of dying or of being readmitted, the ...
Please provide your email address to receive an email when new articles are posted on . DENVER — The first randomized controlled trial of furosemide for preterm infants at high risk for ...
Credit: scPharmaceuticals. Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration. Furoscix ® ...
The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. The influence of furosemide on prognosis after cardiac surgery is not fully ...
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results